Muharrem Muftuoglu, M.D.

Peer-Reviewed Articles

1. Pourebrahim R, Montoya RH, Akiyama H, Ostermann L, Khazaei S, Muftuoglu M, Baran N, Zhao R, Lesluyes T, Liu B, Khoury JD, Gagea M, Van Loo P, Andreeff M. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice. Cell Rep Med:101558. e-Pub 2024. PMID: 38733986.
2. Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9(48):eadh1436, 2023. e-Pub 2023. PMID: 38019903.
3. Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood 142(12):1056-1070, 2023. e-Pub 2023. PMID: 37339579.
4. Yan Z, Li L, Fu D, Wu W, Qiao N, Huang Y, Jiang L, Wu D, Hu Y, Zhang H, Xu P, Cheng S, Wang L, Lacin S, Muftuoglu M, Zhao W. Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Front Med 17(4):699-713, 2023. e-Pub 2023. PMID: 37060525.
5. Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
6. Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
7. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1):80, 2023. e-Pub 2023. PMID: 37193700.
8. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1):57, 2023. e-Pub 2023. PMID: 37088806.
9. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(5):1097, 2022. PMID: 35484266.
10. Li L, Muftuoglu M, Liang S, Basyal M, Lv J, Akdogan ME, Chen K, Andreeff M, Flowers CR, Parmar S. In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight 7(7), 2022. e-Pub 2022. PMID: 35230977.
11. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
12. Mu-Mosley H, Ostermann L, Muftuoglu M, Vaidya A, Bonifant CL, Velasquez MP, Gottschalk S, Andreeff M. Transgenic Expression of IL15 retains CD123-redirected T-cells in a less differentiated state resulting in improved anti-AML activity in autologous AML PDX models. Front Immunol 13:880108, 2022. e-Pub 2022. PMID: 35615350.
13. Miao Q, Wang F, Dou J, Iqbal R, Muftuoglu M, Basar R, Li L, Rezvani K, Chen K. Ab initio spillover compensation in mass cytometry data. Cytometry A 99(9):899-909, 2021. e-Pub 2020. PMID: 33342071.
14. Muftuoglu M, Li L, Liang S, Mak D, Lin AJ, Fang J, Burks JK, Chen K, Andreeff M. Extended live-cell barcoding approach for multiplexed mass cytometry. Sci Rep 11(1):12388, 2021. e-Pub 2021. PMID: 34117319.
15. Liang S, Mohanty V, Dou J, Miao Q, Huang Y, Muftuoglu M, Ding L, Peng W, Chen K. Single-cell manifold-preserving feature selection for detecting rare cell populations. Nat Comput Sci 1(5):374-384, 2021. e-Pub 2021. PMID: 36969355.
16. Yan ZX, Li L, Wang W, OuYang BS, Cheng S, Wang L, Wu W, Xu PP, Muftuoglu M, Hao M, Yang S, Zhang MC, Zheng Z, Li J, Zhao WL. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma. Clin Cancer Res 25(23):6995-7003, 2019. e-Pub 2019. PMID: 31444250.
17. Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med 379(15):1443-1451, 2018. PMID: 30304652.
18. Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32(4):960-970, 2018. e-Pub 2017. PMID: 28972595.
19. Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28(4):432-447, 2018. e-Pub 2018. PMID: 29567676.
20. Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32(2):520-531, 2018. e-Pub 2017. PMID: 28725044.
21. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
22. Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K. A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood 129(6):740-758, 2017. e-Pub 2016. PMID: 27821506.
23. Khoder A, Alsuliman A, Basar R, Sobieski C, Kondo K, Alousi AM, Szydlo R, Muftuoglu M, Shaim H, Apperley JF, Gokdemir E, Cooper N, Mehta RS, Marin D, Champlin R, Shpall E, Rezvani K. Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. Front Immunol 8:1937, 2017. e-Pub 2018. PMID: 29375566.
24. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol 8:1773, 2017. e-Pub 2018. PMID: 29379494.
25. Alsuliman A, Appel SH, Beers DR, Basar R, Shaim H, Kaur I, Zulovich J, Yvon E, Muftuoglu M, Imahashi N, Kondo K, Liu E, Shpall EJ, Rezvani K. A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. Cytotherapy 18(10):1312-24, 2016. e-Pub 2016. PMID: 27497700.
26. Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
27. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
28. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood 124(13):2034-45, 2014. e-Pub 2014. PMID: 25051962.
29. Gurler N, Oksuz L, Muftuoglu M, Sargin F, Besisik S. Bacillus cereus catheter related bloodstream infection in a patient with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 4(1):e2012004, 2012. e-Pub 2012. PMID: 22348186.

Abstracts

1. Muftuoglu M, LiLi, Mahesh Basyal, Edward Ayoub, Jiangxing Lv, Andrea Bedoy, Tallie Patsilevas, Aram Bidikian, Ghasyas Issa, Michael Andreeff. Single-Cell Proteomic Analysis Reveals Menin Inhibition-Induced Proteomic Alterations in AML Patients Treated with Revumenib. 65th ASH Annual Meeting and Exposition, 2023.
2. Muftuoglu M. Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax. 64th ASH Annual Meeting and Exposition, 2022.
3. Yilmaz M, Kantarjian HM, Muftuoglu M, Kadia TM, Konopleva M, Borthakur G, DiNardo CD, Pemmaraju N, Short NJ, Alvarado Y, Moltalban Brava G, Jurisprudencia C, Pike AM, Ohanian M, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML). Journal of Clinical Oncology 39 (15 supplement):e19019. e-Pub 2021.
4. Muftuoglu M, Mak PY, Ruvolo V, Nishida Y, Ruvolo P, Carter BZ, Andreeff M. High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML. 62nd ASH Annual Meeting and Exposition, 2020.
5. Muftuoglu M, Alaniz Z, Mak D, Lin A, Burks J, Carter BZ, Andreeff M. High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins. 62nd ASH Annual Meeting and Exposition, 2020.
6. Chang KH, Muftuoglu M, Zhang W, Basyal M, Ostermann LB, Fogler WE, Magnani JL, Andreeff M. Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy. 62nd ASH Annual Meeting and Exposition, 2020.
7. Yilmaz M, Kantarjian HM, Muftuoglu M, Kadia TM, Konopleva M, Borthakur G, DiNardo CD, Pemmaraju N, Short NJ, Alvarado Y, Moltalban Brava G, Jurisprudencia C, Pike AM, Ohanian M, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial. 62nd ASH Annual Meeting and Exposition, 2020.
8. Shaim H, Alsuliman A, Gabrusiewicz K, Wei J, Yu J, Basar R, Daher M, Kerbauy L, Mendt M, 19. DePombo A, Huertas-Herrera A, Mendt MC, Lim FLWI, Gi Y, Tong Y, Kaur I, Daher M, Basar R, Shaim H, Gokdemir E, Uprety N, Imahashi N, Kerbauy LN, Li L, Liu E, Lu J, Ang S, Bdiwi MH, Jimenez J, Banerjee PP, Champlin RE, Kurtzberg J, Rezvani K, Shpall EJ. Large-Scale, Bioreactor-Generated Expansion of Umbilical Cord Blood Tissue-Derived Mesenchymal Stromal Cells for Clinical Use. 59th ASH Annual Meeting and Exposition, 2017, Atlanta, USA., Li L, Liu E, Imahashi N, Ang S, Gi y, Banarjee PP, Marin D, Champlin RE, Shpall EJ, Heimberger A, Rezvani K. TGF-β is a key mediator of NK cell dysfunction in gliolastoma. AACR, 2017.
9. Muftuoglu M, Li L, Mak D, Shaim H, Burks JK, Xi Y, Hu B, Shaim H, Imahashi N, Bdiwi, MH, Jimenez J, Banarjee PP, Lim F, Kerbauy L, Kaplan M, DePombo A, Mendt MC, Basar R, Daher M, Marin D, Wang J, Andreeff M,. Wierda WG, Jain N, Thompson P, Keating MJ, Armstrong-James D, Champlin RE, Shpall EJ, Rezvani K. Evaluation of T Cell Compartment By Mass Cytometry Reveals Distinct Patterns of Expression of Exhaustion Markers in Chronic Lymphocytic Leukemia. 59th ASH Annual Meeting and Exposition, 2017.
10. Muftuoglu M, Li L, Jimenez J, Mak D, Shaim H, Burks JK, Xi Y, Hu B, Shaim H, Imahashi N, Lim F, Banarjee PP, Bdiwi MH, Kerbauy L, Kaplan M, Armstrong-James D, Champlin RE, Shpall EJ, Rezvani K. Exploring the Cord Blood T Cell Compartment with Mass Cytometry Reveals the Existence of Memory CD4, CD8 and Regulatory T Cell Pools in the Fetal Period. 59th ASH Annual Meeting and Exposition, 2017.
11. Li L, Muftuoglu M, Liu E, Ang S, Lv J, Wan X, Cai R, Chen H, Hu B, Jimenez J, Mak D, Burks JK, Bdiwi MH, Banerjee PP, Imahashi N, Kerbauy L, Lu J, Lim F, Mendt M, DePombo A, Daher M, Basar R, Neelapu S, Orlowski RZ, Andreeff M, Marin D, Champlin R, Shpall EJ, Rezvani K. CS1-Specific Chimeric Antigen Receptor Drives Cord Blood NK Cell Maturation and Expansion In Vivo. 59th ASH Annual Meeting and Exposition, 2017.
12. Li L, Muftuoglu M, Chen H, Mak D, Burks JK, Mehta R, Xi Y, Lv J, Hu B, Jimenez J, Kaplan M, Shaim H, Imahashi N, Banerjee PP, Kerbauy L, Mendt M, Lim, F, Daher M, DePombo A, Basar R, Andreeff M, Wang J, Marin D, Champlin R, Shpall EJ, Rezvani K. NK Cell Diversity Influences Outcomes after Cord Blood Transplantation. 59th ASH Annual Meeting and Exposition, 2017.
13. DePombo A, Huertas-Herrera A, Mendt MC, Lim FLWI, Gi Y, Tong Y, Kaur I, Daher M, Basar R, Shaim H, Gokdemir E, Uprety N, Imahashi N, Kerbauy LN, Li L, Liu E, Lu J, Ang S, Bdiwi MH, Jimenez J, Banerjee PP, Champlin RE, Kurtzberg J, Rezvani K, Shpall EJ. Large-Scale, Bioreactor-Generated Expansion of Umbilical Cord Blood Tissue-Derived Mesenchymal Stromal Cells for Clinical Use. 59th ASH Annual Meeting and Exposition, 2017.
14. Kerbauy LN, Ang S, Liu E, Banerjee PP, Wu Y, Shaim H, Lim FL, Basar R, Li L, Muftuoglu M, Daher M, Imahashi N , Mendt MC, Kaplan M, Mukherjee M, Lee JCH, Orange J, Konopleva M, Andreeff M , Champlin RE, Shpall ES, Rezvani R. Cord Blood NK Cells Engineered to Express a Humanized CD123-Targeted Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia. 59th ASH Annual Meeting and Exposition, 2017.
15. Daher M, Basar R, Shaim H, Gokdemir E, Uprety N, Kontoyiannis A, Mendt MC, Imahashi N, Kerbauy LN, Wei Inng Lim FL, Li L, Muftuoglu M, Banerjee PP, Champlin RE, Ruvolo PP, Andreeff M , Kantarjian HM, Garcia-Manero G, Shpall ES, Rezvani R.. The TGF-b/SMAD signaling pathway as a mediator of NK cell dysfunction and immune evasion in myelodysplastic syndrome. 59th ASH Annual Meeting and Exposition, 2017.
16. Muftuoglu M, Li L, Chen H, Mak D, Gokdemir E, Shaim H, Burks J, Basar R, Imahashi N, Mendt MC, Daher M, Marin D, Wierda WG, Jain N, Keating MJ, Champlin RE, Shpall EJ, Rezvani K. Mass Cytometry Reveals Heterogeneity in the Exhaustion Profile of T-Cells in Chronic Lymphocytic Leukemia and the CD4: CD8 Ratio May be a Reliable Predictor of CD8+ T Cell Compartment" Fitness". 58th ASH Annual Meeting and Exposition, 2016.
17. Muftuoglu M, Ahmed S, Olson A, Mulanovich V, Li L, Verstovsek S, Kaur I, Abueg G, Marin D, Yvon E, Champlin RE, Shpall EJ, Rezvani K. Use of Expanded Allogeneic Third Party BK Virus Specific Cytotoxic T Cells to Target Progressive Multifocal Leukoencephalopathy. 58th ASH Annual Meeting and Exposition, 2016.
18. Olson AL, Muftuoglu M, Kaur I, Li L, Abueg G, Chemaly R, Yvon E, Thall PF, Marin D, Alousi AM, Ahmed S, Hosing C, Ciurea SO, Kebriaei P, Jones R, Andersson BS, Shah N, Oran B, Abudayyeh A, Popat U, Andersson BS, Champlin RE, Shpall EJ, Rezvani K. Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial. 58th ASH Annual Meeting and Exposition, 2016.
19. Oran B, Muftuoglu M, Kaur I, Li L, Yvon E, Abueg G, Bassett R, Thall PF, Marin D, Alousi AM, Ahmed S, Ciurea SO, Shah N, Hosing C, Olson AL, Parmar S, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation. 58th ASH Annual Meeting and Exposition, 2016.
20. Li L, Muftuoglu M, Chen H, Mak D, Gokdemir E, Shaim H, Burks J, Daher M, Imahashi N, Vilchez MC, Basar R, Marin D, Champlin RE, Shpall EJ, Rezvani K. Cytomegalovirus Reactivation Shapes NK Cells Diversity Following Allogeneic Hematopoietic Stem Cell Transplantation. 58th ASH Annual Meeting and Exposition, 2016.
21. Daher M, Marin D, Sobieski C, Shaim H, Basar R, Vilchez MC, Gokdemir E, Li L, Imahashi N, Muftuoglu M, Champlin RE, Shpall EJ, Rezvani K. KIR Gene Haplotype: An Independent Predictor of Clinical Outcome in MDS Patients. 58th ASH Annual Meeting and Exposition, 2016.
22. Shaim H, Alsuliman A, Gabrusiewicz KR, Wei J, Yu J, Basar R, Kondo K, Muftuoglu M, Liu E, Imahashi N, Sobieski C, Tong Y, Yvon E, Champlin R, Shpall E, Heimberger A, Rezvani K. Glioblastoma infiltrating NK cells are dysfunctional and have a severely altered phenotype. NK2015 15th Meeting of the Society for Natural Immunity, 2015.
23. Shaim H, Estrov Z, Sekine T, Kondo K, Ruvolo P, Thompson P, Sarvaria A, Muftuoglu M, Imahashi N, Liu E, Sobieski C, Wierda W, Keating MJ, Shah N, Hosing CM, Alsuliman A, Basar B, Ferrajoli A, Shpall E, Rezvani K. The CXCR4/STAT3/IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia (CLL) and Can be Modulated By Lenalidomide. 57th ASH Annual Meeting and Exposition, 2015.
24. Liu E, Tong Y, Dotti G, Savoldo B, Muftuoglu M, Kondo K, Mukherjee M, Orange JS, Sobieski C, Alsuliman A, Shaim H, Imahasi N, Keating MJ, Hosing CM, Shah N, Wierda W, Champlin RE, Shpall EJ, Rezvani K. Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity. 57th ASH Annual Meeting and Exposition, 2015.
25. Kondo K, Burger JA, Keating MJ, Tran J, Muftuoglu M, Daher M, Shaim H, Thompson P, Imahashi N, Alsuliman A, Wierda W, Liu E, Shpall EJ, Rezvani K. Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions brutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions. 57th ASH Annual Meeting and Exposition, 2015.
26. Shah N, Li L, Kaur I, McCarty J, Yvon E, Shaim H, Muftuoglu M, Liu E, Sobieski C, Orlowski RZ, Cooper LJN, Lee DA, Parmar, S, Cao K, Hosing CM, Ahmed S, Nieto Y, Bashir Q, Patel KK, Bollard CM, McNiece IK, Qazilbash M, Champlin RE, Rezvani K, Shpall EJ. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. 57th ASH Annual Meeting and Exposition, 2015.
27. Muftuoglu M, Alsuliman A, Khoder A, Ahn YO, Liu E, Chew C, Hamdi A, Sekine T, Sarvaria A, Cooper N, De Lavallade H, Marin D, Stringaris K, Verneris MR, Shpall EJ, and Rezvani K. CD161 Expression Identifies a Distinct Subset Of Drug-Effluxing Viral-Specific Memory CD4+ T Cells That Preferentially Survive Cytotoxic Chemotherapy. 55th ASH Annual Meeting and Exposition, 2013.
28. Sarvaria A, Khoder A, Alsuliman A, Chew C, Sekine T, Cooper N, De Lavallade H, Muftuoglu M, Yvon E, Hamdi A, Alousi A, St. John LS, Marin D, Stringaris K, Liu E, Molldrem JJ, Shah N, Parmar S, McNiece IK, Champlin RE, Shpall EJ, Rezvani K. B Cell With Regulatory Function Are Enriched Within Transitional and IgM Memory B Cell Subsets In Healthy Donors But Are Reduced and Functionally Impaired In Patients With Chronic Graft-Versus-Host Disease. 55th ASH Annual Meeting and Exposition, 2013.
29. Muftuoglu M, Alaniz Z, Mak D, Lin A, Burks J, Carter BZ, Andreeff M. High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Patients with Relapsed/Refractory AML. Clinical Lymphoma Myeloma and Leukemia 20:S206-S207.
30. Muftuoglu M, Ruvolo V, Nishida Y, Mak PY, Ruvolo P, Carter BZ, Andreeff M. Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns. Blood, The Journal of the American Society of Hematology 134 (Supplement 1):882.
31. Mu-Mosley H, Ostermann LB, Muftuoglu M, Schober W, Patel NB, Vaidya A, Bonifant CL, Gottschalk S, Velasquez MP, Andreeff M. Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity. Blood, The Journal of the American Society of Hematology 134 (Supplement 1):3917.
32. Kerbauy L, Kaplan M, Banerjee PP, Lim FLWI, Nunes-Cortes AK, Daher D, Mendt MC, Basar R, L Li, Muftuoglu M, Shaim H, Shanley M, Liu E, Ang S, Cai R, Nandivada V, Champlin RE, Koch J, Treder M, Shpall EJ, Rezvani K. Cord Blood Derived Natural Killer Cells Loaded with a Tetravalent Bispecific Antibody Construct (AFM13) As Off-the-Shelf Cell Therapy for CD30+ Malignancies. Blood 132 (Supplement 1):341.
33. Aung FM, Lichtiger B, Kaur I, Muftuoglu M, Shpall E, Rezvani K. Peripheral Blood Mononuclear Cells from Buffy Coats Processed from Healthy Whole Blood Donors for the Production of Third Party Viral Specific Cytotoxic T Lymphocytes. In Transfusıon 57:112A.